• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncolytic Virus Regimens Boost Tumor Response but Carry Higher Toxicity Risks

by
November 11, 2026
in Health
Reading Time: 3 mins read
0
Oncolytic Virus Regimens Boost Tumor Response but Carry Higher Toxicity Risks

Oncolytic Virus Regimens Boost Tumor Response but Carry Higher Toxicity Risks

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive systematic review and network meta-analysis published in the European Journal of Medical Research reveals that cancer treatments incorporating oncolytic viruses can produce superior objective response rates compared with standard systemic therapies, although the therapies are accompanied by a higher risk of severe adverse events. Synthesizing evidence from 18 randomized controlled trials that encompassed 2,922 participants across 11 distinct cancer types, researchers evaluated how various virotherapy approaches stack up against conventional therapeutic protocols. While specific viral regimens demonstrated notable gains in shrinking tumors, the overall body of cumulative evidence remains constrained by substantial statistical imprecision and clinical heterogeneity, warranting careful interpretation.

Oncolytic viruses represent a distinct class of therapeutic agents designed to selectively replicate within and lyse malignant cells while concurrently stimulating systemic antitumor immunity. Despite widespread clinical interest in their potential to transform oncology care, their comparative therapeutic efficacy, safety profiles relative to systemic therapies, and optimal integration into multi-agent treatment protocols have remained uncertain. To address these unresolved clinical questions, an investigative team led by Dongxian Li, Haiting Wang, Yisong Yao, and colleagues systematically gathered and analyzed all accessible comparative trial data to establish relative performance rankings across regimens.

The investigators executed systematic searches across PubMed, Embase, Ovid, Web of Science, and ClinicalTrials.gov, capturing phase II and phase III randomized controlled trials evaluating oncolytic virus platforms through August 30, 2024. The primary analytical outcomes established for the investigation were objective response rate and overall survival, while the primary secondary endpoint tracked the incidence of grade 3 or higher adverse events. To evaluate these metrics robustly, the researchers employed pairwise meta-analysis alongside Bayesian random-effects network meta-analysis, frequentist cross-validation using netmeta, and trial sequential analysis. Sensitivity analyses incorporated 95 percent prediction intervals, prior sensitivity analyses, and evaluations stratified by the tumor immune microenvironment, with certainty of evidence graded according to the GRADE framework.

Monotherapy with T-VEC delivered a network odds ratio of 5.48 with a 95 percent confidence interval spanning 2.36 to 12.73 when contrasted directly against systemic therapies. Beyond these specific interventions, however, most other network comparisons yielded wide confidence intervals crossing unity, demonstrating substantial statistical imprecision across the broader evidentiary network.

Regarding survival outcomes, talimogene laherparepvec exhibited a non-significant numerical trend toward improved overall survival relative to systemic therapies, recording a hazard ratio of 0.75 with a 95 percent confidence interval ranging from 0.49 to 1.15. Further subgroup analyses stratified by therapeutic pairing demonstrated that combinations uniting oncolytic viruses with immune checkpoint inhibitors produced superior objective response rates, generating an odds ratio of 2.92 with a 95 percent confidence interval of 1.48 to 5.73 relative to viral monotherapy or combinations with chemotherapy and targeted agents. This combination approach with checkpoint inhibitors also reflected a parallel trend toward enhanced overall survival, reflected in a hazard ratio of 0.83 with a 95 percent confidence interval of 0.56 to 1.23.

Evaluation of treatment-related toxicity demonstrated that oncolytic virus regimens were generally associated with a numerically higher incidence of severe toxicity than systemic treatments. The trial sequential analysis boundary monitoring the risk of grade 3 or higher adverse events was definitively crossed, confirming an elevated risk of severe complications with virotherapy regimens. Within the network evaluation, talimogene laherparepvec exhibited the highest relative adverse event risk profile, registering an odds ratio of 2.08, though with an extremely wide 95 percent confidence interval spanning 0.36 to 12.0 that highlights persistent network variability. Conversely, the trial sequential analysis for objective response rate revealed that cumulative evidence remains statistically insufficient to draw unshakeable conclusions, requiring an estimated information size of approximately 14,782 patients to achieve conclusive statistical power.

Using the formal GRADE methodology, the investigators rated the overall certainty of evidence for both objective response rate and overall survival as very low, driven primarily by pervasive clinical heterogeneity, methodological risk of bias, and wide credible intervals crossing 1 across comparative network loops. The authors concluded that while current oncolytic virotherapy regimens demonstrate undeniable biological activity, their clinical deployment faces ongoing challenges related to elevated severe adverse events and a deficiency of rigorous, large-scale randomized trials.

Subject of Research: Comparative efficacy and safety of oncolytic viruses versus systemic therapies across randomized cancer clinical trials

Article Title: Efficacy and safety comparison of oncolytic viruses and systemic therapies in cancer: a systematic review with network meta-analysis and trial sequential analysis

Article References: Li, D., Wang, H., Yao, Y., Song, H., Cui, X., Fang, Y., Lv, S., Li, Y., & Song, X. (2026). Efficacy and safety comparison of oncolytic viruses and systemic therapies in cancer: a systematic review with network meta-analysis and trial sequential analysis. European Journal of Medical Research. https://doi.org/10.1186/s40001-026-05335-3

Image Credits: AI Generated

DOI: 10.1186/s40001-026-05335-3

Keywords: Oncolytic viruses, Systemic therapies, Talimogene laherparepvec, H101, Network meta-analysis, Trial sequential analysis, Objective response rate, Overall survival, Grade 3 adverse events, Immune checkpoint inhibitors, Tumour immune microenvironment, Randomized controlled trials, GRADE certainty, Bayesian random-effects model, Required information size, Clinical trial methodology

News Source: Nathaniel Bowman. (November 11, 2026). Oncolytic Virus Regimens Boost Tumor Response but Carry Higher Toxicity Risks. Scienmag.

Tags: Bayesian random-effects modelclinical trial methodologyGrade 3 adverse eventsGRADE certaintyH101Immune checkpoint inhibitorsNetwork Meta-Analysisobjective response rateoncolytic virusesoverall survivalrandomized controlled trialsRequired information sizesystemic therapiesTalimogene laherparepvectrial sequential analysisTumour immune microenvironment
Share12Tweet7Share2ShareShareShare1

Related Posts

Case Details Early Duodenal Perforation During Bevacizumab Therapy for Ovarian Cancer

Case Details Early Duodenal Perforation During Bevacizumab Therapy for Ovarian Cancer

November 19, 2026
Critical Review Evaluates Anti-Tuberculosis Potential and Evidence Gaps in Traditional Ginger Species

Critical Review Evaluates Anti-Tuberculosis Potential and Evidence Gaps in Traditional Ginger Species

November 19, 2026

International HIV Dementia Scale Outperforms Montreal Cognitive Assessment in Ethiopian Screening Study

November 19, 2026

Pilot Trial Shows Integrated Lifestyle Intervention Is Feasible for Cancer Patients

November 19, 2026

POPULAR NEWS

  • Review Outlines Extraction and Health Benefits of Blackcurrant Polysaccharides

    Review Outlines Extraction and Health Benefits of Blackcurrant Polysaccharides

    29 shares
    Share 12 Tweet 7
  • Canadian Focus Groups Reveal Core Lessons for Wildlife One Health Integration

    29 shares
    Share 12 Tweet 7
  • Bevacizumab Biosimilar Shows Similar Blood Clot Risk to Reference Drug in Cancer Study

    29 shares
    Share 12 Tweet 7
  • Biotelemetry Array Identifies Wild Murray Cod Nesting Sites in Turbid Waters

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Pre-Fermentation Seed Tannin Size Reshapes Phenolic Chemistry and Astringency in Marselan Wine

Case Details Early Duodenal Perforation During Bevacizumab Therapy for Ovarian Cancer

Critical Review Evaluates Anti-Tuberculosis Potential and Evidence Gaps in Traditional Ginger Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 90 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.